Katherine Stultz, a C-level executive, develops cultures, inspires teams, and steers organizations to challenge the status quo and achieve previously unimagined organizational and profitability goals. She is an entrepreneurially driven corporate leader with a record of success in building from startup through commercial launch. She engages and motivates her teams to deliver global, life enhancing standard of care treatments for patients.
Katherine was the chief operating officer for Graphite Bio, a clinical-stage, next-generation gene editing company pioneering a precision gene editing platform. Emerging from stealth to IPO in less than 14 months, she joined as the second executive leader for the company and was empowered to build the organization from the ground up.
Prior to this, Katherine was vice president, general manager for Spain and Portugal at Celgene Corporation. Earlier at Celgene, Katherine held progressive positions of increasing responsibility in global project leadership, hematology and oncology, marketing, sales management, market access, and project leadership as the organization grew from a small biotech to a preeminent biotech. Katherine began her career at Eli Lilly & Company and ConvaTec, a Bristol-Myers Squibb company.
She holds a Bachelor of Science in mechanical engineering (biomedical applications) from Cornell University in New York and has attended executive leadership development programs at the Darden School of Business, IESE Business School in Barcelona, Spain, and the International Institute for Management Development (IMD) in Switzerland.